{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Non-Small+Cell+Lung+Cancer", "query": { "condition": "First Line Non-Small Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 264, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Non-Small+Cell+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T07:11:23.071Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05215340", "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Datopotamab Deruxtecan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2022-03-04", "completion_date": "2032-03-04", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 31, "location_summary": "Chandler, Arizona • Los Angeles, California • Santa Barbara, California + 19 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05215340" }, { "nct_id": "NCT00666692", "title": "A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2008-04", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-04-27", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 4, "location_summary": "Bethesda, Maryland • Hershey, Pennsylvania • Greenville, South Carolina + 1 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Yakima", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666692" }, { "nct_id": "NCT01523587", "title": "LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "afatinib", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 795, "start_date": "2012-03-05", "completion_date": "2017-12-27", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 33, "location_summary": "Chandler, Arizona • La Jolla, California • Sacramento, California + 27 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01523587" }, { "nct_id": "NCT07355205", "title": "First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer Stage IV", "Non-small Cell Lung Cancer Recurrent" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Nogapendekin alfa inbakicept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2026-07-07", "completion_date": "2032-07-31", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07355205" }, { "nct_id": "NCT03976323", "title": "Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Nonsquamous Non-small-cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1003, "start_date": "2019-06-28", "completion_date": "2026-01-29", "has_results": true, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Muscle Shoals, Alabama • Burbank, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Orange City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03976323" }, { "nct_id": "NCT00716534", "title": "Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "ABT-869", "type": "DRUG" }, { "name": "Placebo for ABT-869", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2008-06", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2013-04-29", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 13, "location_summary": "Chandler, Arizona • Peoria, Arizona • Miami, Florida + 9 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00716534" }, { "nct_id": "NCT00701870", "title": "Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "ezatiostat hydrochloride (Telintra®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2008-10", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2013-11-27", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 24, "location_summary": "Alhambra, California • Anaheim, California • Burbank, California + 20 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00701870" }, { "nct_id": "NCT04911166", "title": "Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Atezolizumab and Interleukin-12 Gene Therapy", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2021-10-14", "completion_date": "2025-04-01", "has_results": false, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04911166" }, { "nct_id": "NCT04738487", "title": "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasms", "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Pembrolizumab/Vibostolimab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1264, "start_date": "2021-04-07", "completion_date": "2026-01-27", "has_results": true, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 7, "location_summary": "Boca Raton, Florida • Peoria, Illinois • Springfield, Missouri + 4 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Springfield", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04738487" }, { "nct_id": "NCT02846792", "title": "Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "ALK Gene Translocation", "EGFR Activating Mutation", "Recurrent Non-Small Cell Lung Carcinoma", "ROS1 Gene Translocation", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IV Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-06-14", "completion_date": "2018-08-16", "has_results": true, "last_update_posted_date": "2019-03-04", "last_synced_at": "2026-07-22T07:11:23.071Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02846792" } ] }